Takhzyro Alternatives Compared
Takhzyro | Orladeyo | Firazyr |
|
---|
Takhzyro (lanadelumab) | Orladeyo (berotralstat) | Firazyr (icatibant) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Takhzyro works by binding to a protein called kallikrein and inhibiting its activity and may be used to prevent hereditary angioedema (HAE) attacks in adults, adolescents, and children aged 2 years... View more |
Prescription only
Orladeyo is an oral, once-daily medication that is taken to reduce angioedema attacks in adults and children over the age of 12 with HAE. It is the only oral preventive currently available (the... View more |
Prescription only
Firazyr is used to treat attacks of hereditary angioedema (HAE) in adults (not children) and people can be taught how to self-administer it subcutaneously at home. Injection site reactions, such as... View more |
Related suggestions |
|||||||||||||||||||||||
More about Takhzyro (lanadelumab) | More about Orladeyo (berotralstat) | More about Firazyr (icatibant) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Takhzyro has an average rating of 10.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Orladeyo has an average rating of 6.7 out of 10 from a total of 3 ratings on Drugs.com. 33% of reviewers reported a positive effect, while 0% reported a negative effect. |
Firazyr has an average rating of 7.9 out of 10 from a total of 7 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 29% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: Takhzyro side effects in more detail. |
See also: Orladeyo side effects in more detail. |
See also: Firazyr side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Takhzyro prices |
View all Orladeyo prices |
View all Firazyr prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
360 hours |
152 hours |
1.8 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 2 drugs are known to interact with Takhzyro:
|
A total of 450 drugs are known to interact with Orladeyo:
|
A total of 11 drugs are known to interact with Firazyr:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
August 23, 2018 |
December 03, 2020 |
N/A |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.